Dexmedetomidine
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 28/100
28
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Brain Injuries
Conditions
Acute Brain Injuries
Trial Timeline
Apr 1, 2014 → Apr 1, 2015
NCT ID
NCT02252523About Dexmedetomidine
Dexmedetomidine is a phase 2 stage product being developed by Orion Corporation for Acute Brain Injuries. The current trial status is unknown. This product is registered under clinical trial identifier NCT02252523. Target conditions include Acute Brain Injuries.
What happened to similar drugs?
20 of 20 similar drugs in Acute Brain Injuries were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
4
Company
12
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03813277 | Approved | Completed |
| NCT02252523 | Phase 2 | UNKNOWN |
| NCT01266252 | Phase 3 | Completed |
| NCT00747721 | Phase 1 | Completed |
| NCT00226785 | Phase 3 | Terminated |
Competing Products
20 competing products in Acute Brain Injuries